Capital Diagnostics LLC

Capital Diagnostics LLC was paid $11.58M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 43% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Maryland

Rank by total paid#4 of 93

Median peer was paid$430K

This provider vs. median27×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	13,885	$1.39M
2019	22,525	$1.95M
2020	22,773	$1.76M
2021	33,226	$2.60M
2022	24,060	$1.83M
2023	18,172	$1.08M
2024incomplete	18,846	$966K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	43%	56,459	35,390	$5.01M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	22%	30,788	14,968	$2.51M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	20%	47,656	27,565	$2.36M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	14%	13,451	10,065	$1.67M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	310	301	$27K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	44	37	$1K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	732	425	$910.86
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	107	88	$637.49
84443	Thyroid stimulating hormone (TSH)	<1%	125	100	$599.95
83036	Hemoglobin; glycosylated (A1C)	<1%	163	137	$385.50
84481		<1%	47	42	$298.99
80061	Lipid panel	<1%	66	59	$278.00

28 more codes

84439		<1%	84	$275.94
80048	Basic metabolic panel (calcium, ionized)	<1%	598	$246.22
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	515	$233.25
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	575	$172.80
36415	Collection of venous blood by venipuncture	<1%	163	$159.17
80053	Comprehensive metabolic panel	<1%	198	$115.62
81003		<1%	140	$64.68
87086	Culture, bacterial; quantitative colony count, urine	<1%	56	$58.60
82746		<1%	15	$43.08
82040		<1%	17	$18.46
87088		<1%	15	$6.35
82570		<1%	116	$4.06
80349		0%	57	$0.00
80367		0%	57	$0.00
80353		0%	57	$0.00
80359		0%	57	$0.00
85018		0%	124	$0.00
80324		0%	58	$0.00
80358		0%	57	$0.00
80372		0%	57	$0.00
80356		0%	57	$0.00
80373		0%	57	$0.00
80348		0%	57	$0.00
80369		0%	57	$0.00
80354		0%	57	$0.00
80346		0%	57	$0.00
85014		0%	124	$0.00
83992		0%	57	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBHATNAGAR, RAMNEESH (OWNER)